{
    "Trade/Device Name(s)": [
        "LIAISON Calprotectin",
        "LIAISON Q.S.E.T. Device Plus"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K213858",
    "Predicate Device Reference 510(k) Number(s)": [
        "K182698"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NXO"
    ],
    "Summary Letter Date": "July 26, 2022",
    "Summary Letter Received Date": "December 10, 2021",
    "Submission Date": "December 9, 2021",
    "Regulation Number(s)": [
        "21 CFR 866.5180"
    ],
    "Regulation Name(s)": [
        "Fecal Calprotectin Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Calprotectin"
    ],
    "Specimen Type(s)": [
        "Human stool"
    ],
    "Specimen Container(s)": [
        "LIAISON Q.S.E.T. Device Plus",
        "LIAISON Q.S.E.T. Device",
        "Polypropylene mixing tube with sampling wand and funnel"
    ],
    "Instrument(s)/Platform(s)": [
        "LIAISON Analyzer Family",
        "LIAISON XL Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Sandwich assay using monoclonal antibodies"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Specimen collection device",
        "Extraction kit"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON Calprotectin CLIA assay and Q.S.E.T. Device Plus for quantitative measurement of fecal calprotectin in human stool",
    "Indications for Use Summary": "Quantitative in vitro measurement of fecal calprotectin in human stool as an aid in diagnosing inflammatory bowel diseases and differentiating IBD from irritable bowel syndrome, performed on LIAISON Analyzer Family and used with Q.S.E.T. Device Plus for specimen preparation",
    "fda_folder": "Immunology"
}